2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
Other solid neoplasm
3
Tumor-Agnostic
2
Thoracic
2
Gastrointestinal
2
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Trastuzumab
732
Paclitaxel
695
Cyclophosphamide
647
Docetaxel
560
Capecitabine
486
Letrozole
437
Fulvestrant
400
Carboplatin
398
Doxorubicin
341
Tamoxifen
308
Anastrozole
279
pembrolizumab
274
exemestane
258
Epirubicin
251
pertuzumab
240
Radiotherapy
239
palbociclib
224
Bevacizumab
222
Gemcitabine
215
Vinorelbine
197
Lapatinib
181
130-nm albumin-bound paclitaxel
172
Magnetic Resonance Spectroscopy
164
Albumin-Bound Paclitaxel
157
eribulin
154
Surveys and Questionnaires
152
Exercise
151
Drug Therapy
141
Taxes
134
Fluorouracil
133
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
brigimadlin
×
Breast
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn